Literature DB >> 29934358

Factors associated with anal cancer screening follow-up by high-resolution anoscopy.

Kaan Z Apaydin1, Andy Nguyen2, Christina P C Borba3,4, Derri L Shtasel2,5, Sharon Ulery1, Kenneth H Mayer1,2, Alex S Keuroghlian1,2,5.   

Abstract

OBJECTIVES: High-resolution anoscopy (HRA) is a potential screening method for detection of anal cancer precursors. We evaluated factors associated with adherence to recommended HRA follow-up time intervals among men who have sex with men (MSM).
METHODS: We employed a retrospective, observational cohort study with 155 MSM screened by HRA between 1 April 2011 and 31 March 2016 at a Federally Qualified Health Centre in Boston, Massachusetts.
RESULTS: The sample was 80% white, with a median age of 48 (non-normal distribution, IQR 15). All patients were assigned male sex at birth and none identified as transgender. Fifty patients (32%) followed up with a HRA appointment within 6 months of previous HRA detection of anal high-grade squamous intraepithelial lesion (HSIL). Among patients, 112 (72%) were HIV infected, 56 (36%) had a syphilis diagnosis during the study period, 89 (57.4%) had initiated Hepatitis A or B vaccination series, 70 (45.2%) accessed case management services and 19 (12.3%) utilised pre-exposure prophylaxis (PrEP). In bivariate analysis, patients who underwent recommended follow-up HRA within 6 months of HSIL diagnosis were less likely to report: case management utilisation (p=0.023), initiation of Hepatitis A or B vaccination (p=0.047), HIV diagnosis (p<0.001) and syphilis diagnosis (p=0.001), but were more likely to use HIV PrEP (p<0.001). In binomial logistic regression modelling after adjusting for age and race/ethnicity, patients who had follow-up with HRA within a recommended period of 6 months after HSIL diagnosis were less likely to have initiated Hepatitis A or B vaccination (adjusted OR 0.43, 95% CI 0.20 to 0.94), more likely to use PrEP (adjusted OR 4.47, 95% CI 1.30 to 15.49) and less likely to have a syphilis diagnosis (adjusted OR 0.34, 95% CI 0.14 to 0.86).
CONCLUSIONS: Three-quarters of patients with HSIL did not have follow-up HRA within the clinic's recommended follow-up period of 6 months following HSIL diagnosis by HRA. Future studies ought to explore whether addressing anal health during other STI-related care helps improve adherence to recommended time intervals for follow-up HRA. Given the high prevalence of STI and PrEP use, studies might also evaluate whether integrating HRA follow-up with other sexual health screenings helps improve adherence to recommended HRA follow-up. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Hiv; Hpv; anogenital cancer; gay men; screening

Mesh:

Year:  2018        PMID: 29934358     DOI: 10.1136/sextrans-2017-053515

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  3 in total

1.  The other side of screening: predictors of treatment and follow-up for anal precancers in a large health system.

Authors:  Richard Silvera; Tyler Martinson; Michael M Gaisa; Yuxin Liu; Ashish A Deshmukh; Keith Sigel
Journal:  AIDS       Date:  2021-11-01       Impact factor: 4.177

2.  Do immune inflammatory markers correlate with anal dysplasia and anal cancer risk in patients living with HIV?

Authors:  Jonathan Stem; Qiuyu Yang; Evie Carchman; Robert Striker; Cristina B Sanger
Journal:  Int J Colorectal Dis       Date:  2022-03-25       Impact factor: 2.571

3.  Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay.

Authors:  Luisa Galati; Jean-Damien Combes; Florence Le Calvez-Kelm; Sandrine McKay-Chopin; Nathalie Forey; Mathis Ratel; James McKay; Tim Waterboer; Lea Schroeder; Gary Clifford; Massimo Tommasino; Tarik Gheit
Journal:  Microbiol Spectr       Date:  2022-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.